Scandion Oncology A/S Obtains Positive Preclinical Results in Antibiotic Resistance

Scandion Oncology A/S (Scandion Oncology) hereby announces that Scandion Oncology, together with University of Copenhagen, has discovered that a number of Scandion Oncology’s compounds are able to overcome antibiotic resistance in bacterial infections through a new mechanism of action. These are findings from preclinical studies. The discovery may pave the way for new drugs for treatment of antibiotic resistance.


Smart Innovations  

What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!